Literature DB >> 8640066

c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi.

A Ohashi1, Y Funasaka, M Ueda, M Ichihashi.   

Abstract

To investigate the role of c-KIT receptor in melanocytic tumour development and progression, we analysed the expression and localization of c-KIT by immunohistochemistry and Western blotting. In contrast to the positive staining shown by melanocytes and naevus cells in the epidermis of common naevi (n=20), all dysplastic naevi (n=13) were negative, as were dermal melanocytic cells of blue naevi (n = 4) and common naevi (n = 26). Three out of four superficial spreading melanomas lost c-KIT expression both in the epidermal and dermal parts, while nodular melanomas showed no expression of c-KIT except in partially positive cells, and six out of seven metastatic melanomas were negative. In acral lentiginous melanomas (n = 8), in contrast to other types of melanoma, all cases with melanoma cells growing basally in the epidermis showed strong c-KIT positivity, but melanoma cells growing at the upper layers of the epidermis and vertically into the dermis lost c-KIT expression. Using the Western blot method on cultured pigment cells, human epidermal melanocytes, junctional naevus cells and one out of three metastatic melanoma cell lines showed 125 and 145 kDa bands corresponding to c-KIT, whereas dermal naevus cells did not. These results suggest that dysplastic naevi are distinct from ordinary naevi in terms of c-KIT expression and that basally growing cells in acral lentigenous melanomas could be at an initial stage of tumour progression, before c-KIT loss occurs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640066     DOI: 10.1097/00008390-199602000-00004

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

1.  Molecular alterations in malignant blue nevi and related blue lesions.

Authors:  Ismail Yilmaz; Mehmet Gamsizkan; Sule Ozturk Sari; Banu Yaman; Cuyan Demirkesen; Aylin Heper; Aylin Orgen Calli; Gizem Narli; Zafer Kucukodaci; Ufuk Berber; Dilaver Demirel; Taner Akalin; Murat Demiriz; Nesimi Buyukbabani
Journal:  Virchows Arch       Date:  2015-09-24       Impact factor: 4.064

2.  Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Authors:  Alison C Macleod; Lillian R Klug; Janice Patterson; Diana J Griffith; Carol Beadling; Ajia Town; Michael C Heinrich
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

3.  Reduced GNG2 expression levels in mouse malignant melanomas and human melanoma cell lines.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Yuji Naito; Toshikazu Yoshikawa; Hiro Takahashi; Yoko Funasaka; Tamio Suzuki; Masashi Kato
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

4.  C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma.

Authors:  Rosario S Rivera; Hitoshi Nagatsuka; Mehmet Gunduz; Beyhan Cengiz; Esra Gunduz; Chong Huat Siar; Hidetsugu Tsujigiwa; Ryo Tamamura; Kok Ng Han; Noriyuki Nagai
Journal:  Virchows Arch       Date:  2007-12-08       Impact factor: 4.064

5.  Dose-dependent severe cutaneous reactions to imatinib.

Authors:  S Ugurel; R Hildenbrand; E Dippel; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

6.  Functional assessment of human coding mutations affecting skin pigmentation using zebrafish.

Authors:  Zurab R Tsetskhladze; Victor A Canfield; Khai C Ang; Steven M Wentzel; Katherine P Reid; Arthur S Berg; Stephen L Johnson; Koichi Kawakami; Keith C Cheng
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

7.  Current research and development of chemotherapeutic agents for melanoma.

Authors:  Kyaw Minn Hsan; Chun-Chieh Chen; Lie-Fen Shyur
Journal:  Cancers (Basel)       Date:  2010-04-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.